Tofogliflozin (hydrate) – 5 mg

Brand:
Cayman
CAS:
1201913-82-7
Storage:
-20
UN-No:
De Minimis - 3077 / 9

Tofogliflozin is a potent inhibitor of sodium glucose cotransporter 2 (SGLT2) with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2, respectively.{38569} It is selective for SGLT2 (IC50 = 2.9 nM) over other SGLTs (IC50s = >1,500 nM for SGLT1 and 3-6). Tofogliflozin (3-10 mg/kg) reduces plasma glucose concentrations and increases renal glucose clearance in Zucker diabetic fatty rats in a dose-dependent manner. It also reduces hyperglycemia in non-fasted db/db mice and decreases postprandial hyperglycemia in GK rats, a non-obese model of type 2 diabetes with glucose intolerance.  

 

Available on backorder

SKU: 23509 - 5 mg Category:

Description

A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2, respectively); selective for SGLT2 (IC50 = 2.9 nM) over other SGLTs (IC50s = >1,500 nM for SGLT1 and 3-6); reduces plasma glucose concentration and increases renal glucose clearance in Zucker diabetic fatty rats in a dose-dependent manner when administered at doses ranging from 3-10 mg/kg; reduces hyperglycemia in non-fasted db/db mice and decreases postprandial hyperglycemia in GK rats, a non-obese model of type 2 diabetes with glucose intolerance,


Formal name: (1S,3’R,4’S,5’S,6’R)-6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, monohydrate

Synonyms: 

Molecular weight: 404.5

CAS: 1201913-82-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes